Alpha-thalassemia

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Alpha-thalassemia
Synonyms	α-thalassemia
Pronounce
Specialty	Hematology
Symptoms	Anemia, fatigue, pallor, jaundice, splenomegaly
Complications	Hydrops fetalis, iron overload
Onset	Birth
Duration	Lifelong
Types	Alpha-thalassemia trait, Hemoglobin H disease, Hemoglobin Bart's hydrops fetalis
Causes	Genetic mutations in the HBA1 and HBA2 genes
Risks	Family history, Southeast Asian, Mediterranean, Middle Eastern, African descent
Diagnosis	Complete blood count, hemoglobin electrophoresis, genetic testing
Differential diagnosis	Beta-thalassemia, iron deficiency anemia, sideroblastic anemia
Prevention	Genetic counseling
Treatment	Blood transfusion, iron chelation therapy, bone marrow transplant
Medication	Deferoxamine, Deferasirox
Prognosis	Variable, depending on type
Frequency	Common in certain populations
Deaths	N/A

Blood cell lineage

Alpha-thalassemia

Red Blood Cell abnormalities

Alpha-thalassemia is a blood disorder that reduces the production of hemoglobin. Hemoglobin is the protein in red blood cells that carries oxygen to cells throughout the body. Alpha-thalassemia is caused by mutations in the HBA1 and HBA2 genes, which are responsible for the production of alpha-globin, a component of hemoglobin.

Pathophysiology

In alpha-thalassemia, the production of alpha-globin chains is reduced or absent. This leads to an imbalance in the ratio of alpha to beta-globin chains, resulting in the formation of abnormal hemoglobin molecules. The severity of the disease depends on the number of affected alpha-globin genes.

Genetic Basis

The HBA1 and HBA2 genes are located on chromosome 16. Each person has four alpha-globin genes, two from each parent. The severity of alpha-thalassemia is determined by the number of gene deletions:

• Silent Carrier: One gene deletion, usually asymptomatic.
• Alpha-thalassemia Trait: Two gene deletions, mild anemia.
• Hemoglobin H Disease: Three gene deletions, moderate to severe anemia.
• Hydrops Fetalis: Four gene deletions, usually fatal before or shortly after birth.

Clinical Features

The clinical presentation of alpha-thalassemia varies depending on the number of affected genes.

Silent Carrier

Individuals with one deleted alpha-globin gene are typically asymptomatic and have normal hematological parameters.

Alpha-thalassemia Trait

Individuals with two deleted alpha-globin genes may have mild anemia and microcytosis. They are often asymptomatic and may be identified during routine blood tests.

Hemoglobin H Disease

This condition results from the deletion of three alpha-globin genes. It is characterized by:

• Moderate to severe anemia
• Splenomegaly
• Jaundice
• Bone deformities

Hydrops Fetalis

This is the most severe form of alpha-thalassemia, resulting from the deletion of all four alpha-globin genes. It leads to:

• Severe anemia
• Heart failure
• Edema
• Usually results in stillbirth or death shortly after birth

Diagnosis

Diagnosis of alpha-thalassemia involves:

• Complete blood count (CBC) showing microcytic anemia
• Hemoglobin electrophoresis
• Genetic testing to identify deletions in the HBA1 and HBA2 genes

Management

Management of alpha-thalassemia depends on the severity of the disease:

• Silent Carrier and Alpha-thalassemia Trait: Usually require no treatment.
• Hemoglobin H Disease: May require regular blood transfusions, folic acid supplementation, and splenectomy in severe cases.
• Hydrops Fetalis: Prenatal diagnosis and counseling are important. Intrauterine transfusions may be considered.

Prognosis

The prognosis of alpha-thalassemia varies:

• Silent carriers and individuals with alpha-thalassemia trait generally have a normal life expectancy.
• Hemoglobin H disease can lead to complications but is manageable with treatment.
• Hydrops fetalis is usually fatal without intervention.

Prevention

Genetic counseling is recommended for at-risk couples. Prenatal testing can identify affected fetuses, allowing for informed decision-making.

See Also

• Thalassemia
• Hemoglobinopathy
• Anemia